Cover Image
市場調查報告書

肢端肥大症:開發中產品分析

Acromegaly - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192431
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
肢端肥大症:開發中產品分析 Acromegaly - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 80 Pages
簡介

肢端肥大症,是成人期垂體生長激素過剩而發病的荷爾蒙障礙。有體臭,容易累,頭痛,巨大的腳,身長過高,關節周圍的骨頭部位腫,牙齒的間隔寬廣,睡眠呼吸中止症等症狀。治療中,包含外科手術,多巴胺促效劑,生長激素拮抗劑等。

本報告提供肢端肥大症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

肢端肥大症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Aegis Therapeutics, LLC
  • Antisense Therapeutics Limited
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Foresee Pharmaceuticals, LLC
  • Glide Pharmaceutical Technologies Limited
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Peptron, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ATL-1103
  • BIM-23A758
  • COR-005
  • FP-002
  • G-02113
  • ISIS-GHRLRx
  • ITF-2984
  • L-779976
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate long acting
  • octreotide acetate SR
  • octreotide SR
  • pasireotide ER
  • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors
  • Somadex
  • SXN-101742
  • SXN-101959

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9189IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 8 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acromegaly - Overview
    • Acromegaly - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Acromegaly - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Acromegaly - Companies Involved in Therapeutics Development
    • Aegis Therapeutics LLC
    • Amryt Pharma plc
    • Antisense Therapeutics Ltd
    • Chiasma Inc
    • Crinetics Pharmaceuticals Inc
    • Daewoong Pharmaceutical Co Ltd
    • Dauntless Pharmaceuticals Inc
    • DexTech Medical AB
    • Foresee Pharmaceuticals LLC
    • Glide Pharmaceutical Technologies Ltd
    • Ionis Pharmaceuticals Inc
    • Ipsen SA
    • Italfarmaco SpA
    • Midatech Pharma Plc
    • Novartis AG
    • Peptron Inc
    • Silence Therapeutics Plc
    • Strongbridge Biopharma plc
    • Sun Pharma Advanced Research Company Ltd
  • Acromegaly - Drug Profiles
    • Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atesidorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIM-23B065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-GHRLRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITF-2984 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-779976 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate long acting - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Somadex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SXN-101959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veldoreotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acromegaly - Dormant Projects
  • Acromegaly - Discontinued Products
  • Acromegaly - Product Development Milestones
    • Featured News & Press Releases
      • Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
      • Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
      • Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
      • Dec 02, 2016: Amryt Pharma provides update on AP-102
      • Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
      • Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
      • Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
      • Jul 13, 2016: ATL1103 Patent Update
      • Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
      • Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
      • Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
      • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
      • May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
      • May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
      • Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acromegaly, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Acromegaly - Pipeline by Amryt Pharma plc, H1 2017
  • Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2017
  • Acromegaly - Pipeline by Chiasma Inc, H1 2017
  • Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by DexTech Medical AB, H1 2017
  • Acromegaly - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Acromegaly - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
  • Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by Ipsen SA, H1 2017
  • Acromegaly - Pipeline by Italfarmaco SpA, H1 2017
  • Acromegaly - Pipeline by Midatech Pharma Plc, H1 2017
  • Acromegaly - Pipeline by Novartis AG, H1 2017
  • Acromegaly - Pipeline by Peptron Inc, H1 2017
  • Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2017
  • Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2017
  • Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Acromegaly - Dormant Projects, H1 2017
  • Acromegaly - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Acromegaly, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top